[{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Action Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Action Research Group","highestDevelopmentStatusID":"11","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Action Research Group"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Maastricht University Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ McMaster University","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Addiction and Mental Health \/ McMaster University"},{"orgOrder":0,"company":"Theracos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Theracos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theracos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theracos \/ Undisclosed"},{"orgOrder":0,"company":"VA Ann Arbor Healthcare System","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"VA Ann Arbor Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Ann Arbor Healthcare System \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"11","companyTruncated":"VA Ann Arbor Healthcare System \/ U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"STRONG STAR Multidisciplinary PTSD Research Consortium | South Texas Veterans Health Care System | U.S. Army Medical Research and Development Command | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Texas Health Science Center at San Antonio \/ STRONG STAR Multidisciplinary PTSD Research Consortium | South Texas Veterans Health Care System | U.S. Army Medical Research and Development Command | US Department of Defense","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ STRONG STAR Multidisciplinary PTSD Research Consortium | South Texas Veterans Health Care System | U.S. Army Medical Research and Development Command | US Department of Defense"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"National Institute of Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ National Institute of Mental Health","highestDevelopmentStatusID":"11","companyTruncated":"Alto Neuroscience \/ National Institute of Mental Health"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Melbourne \/ Pfizer Inc"},{"orgOrder":0,"company":"Anagnostou, Evdokia, M.D.","sponsor":"Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU ","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"Anagnostou, Evdokia, M.D.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anagnostou, Evdokia, M.D. \/ Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU ","highestDevelopmentStatusID":"8","companyTruncated":"Anagnostou, Evdokia, M.D. \/ Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU "},{"orgOrder":0,"company":"Randi J. Hagerman, MD","sponsor":"Health Resources and Services Administration","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"Randi J. Hagerman, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Randi J. Hagerman, MD \/ Health Resources and Services Administration","highestDevelopmentStatusID":"8","companyTruncated":"Randi J. Hagerman, MD \/ Health Resources and Services Administration"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Sertraline
Details :
Sertraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Sertraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Details :
Rexulti (brexpiprazole) 5-HT2A receptor, is being evaluated in combination with sertraline in late-stage clinical trials with adult patients for the treatment of post-traumatic stress disorder.
Details :
Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder.
Sponsor :
Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU
Details :
Sertraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neurodevelopmental Disorders.
Sponsor :
Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU
Details :
Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Details :
Sertraline hydrochloride potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT). It is indicated for the treatment of MDD, PTSD, PMDD, panic disorder, and social anxiety disorder.
Sponsor :
Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un
Details :
Sertraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obsessive-Compulsive Disorder.
Sponsor :
Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un
Details :
Sertraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder, Major.
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
